The Future Costs, Risks and Rewards of Drug Development: The Economics of Pharmacogenomics

Published

This article, published in the July 2009 issue of PharmacoEconomics, discusses the evolving field of pharmacogenomics--which is the science of using genomic markers to predict drug response--and how it may impact the future costs, risks and returns to pharmaceutical research and development (R&D). Authors Joseph Cook and Graeme Hunter of NERA Economic Consulting and John A. Vernon of the University of North Carolina at Chapel Hill uncover a number of factors and issues that are likely to influence the expected returns and, hence, the incentive to invest in new pharmaceutical R&D in tandem with the development of pharmacgenomics.

Due to copyright issues, the article must be downloaded from the PharmacoEconomics website. Limited copies of the article are available from NPC.